ANTICIPATING TREATMENT NON-PERSISTENCE THROUGH AN INNOVATIVE CONCEPTUAL FRAMEWORK

Published Mar 7, 2015
Paderborn, Germany - Using principles from behavioral economics to model patient decisions, innovative research published in Value in Health proposes a framework to understand the reasons for treatment non-persistence and predicts the point at which a patient will stop taking their medication. This information could contribute to the development of tailored intervention solutions to ensure the patient stays on track and continues taking their medicine as prescribed. The conceptual model described in the article, “Conceptual Model and Economic Experiments to Explain Non-persistence and Enable Mechanism Designs Fostering Behavioral Change,” bridges the economic principles of loss aversion and mental accounting with health behavior. The model highlights that a point exists where a patient feels that they have been adequately compensated for their perceived losses, such as effort to travel to see their doctor, or loss of day at work because of ill health. It is at this point that they will stop taking their medicine and thus the benefit of persistence is no longer greater than non-persistence. “This research will equip health care professionals with a way to generate insights on patient persistence behaviors. The incorporation of this intelligence into existing strategies could lead to more sophisticated, personalized tools that work towards maintaining treatment compliance.” said co-author Prof. Dr. René Fahr, PhD, from the University of Paderborn in Paderborn, Germany. Whereas previous research has limitations in its focus solely on rational choice behavior or retrospective identification of correlations between behaviors and discontinuation, this conceptual model is prospective, scalable and can be calibrated. In practice, it may therefore result in better health outcomes for patients and a reduction in costs through more efficient health care delivery.

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×